DNALite Therapeutics is a preclinical biotechnology company founded in 2016 with a focus on transforming proteins into oral drugs. The company's pioneering oral therapies for intestinal delivery of mRNA and pDNA are aimed at leveraging the unique properties of the gastrointestinal tract to secrete proteins into the bloodstream.
The company's slogan, "Pioneering oral therapies for intestinal delivery of mRNA and pDNA, transforming proteins into oral drugs," encapsulates their innovative approach to drug delivery. DNALite Therapeutics has received a Convertible Note investment on 07 March 2023 from notable investors including SOSV and indiebio.
DNALite Therapeutics operates within the Biotechnology and Health Care industries, positioning itself at the forefront of advancements in oral medication technologies.
Overall, DNALite Therapeutics' pioneering approach to oral lipid nanoparticle technology and its recent investment from renowned investors underscore the company's potential to revolutionize drug delivery methods, making it a compelling prospect for venture capital firms seeking innovative biotech opportunities.
